Barclays Issues Pessimistic Forecast for bluebird bio (NASDAQ:BLUE) Stock Price

bluebird bio (NASDAQ:BLUE) had its price objective trimmed by Barclays from $4.00 to $2.00 in a report published on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company’s stock.

A number of other research analysts have also issued reports on the stock. JPMorgan Chase & Co. lowered shares of bluebird bio from a “neutral” rating to an “underweight” rating in a report on Friday. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 target price on shares of bluebird bio in a report on Thursday, August 15th. Wells Fargo & Company reduced their target price on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating on the stock in a report on Wednesday, September 25th. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. Finally, Robert W. Baird reduced their target price on shares of bluebird bio from $7.00 to $6.00 and set an “outperform” rating on the stock in a report on Thursday, August 15th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $3.03.

bluebird bio Price Performance

Shares of NASDAQ:BLUE traded down $0.04 on Friday, reaching $0.32. 9,162,727 shares of the company were exchanged, compared to its average volume of 7,439,042. bluebird bio has a 1-year low of $0.32 and a 1-year high of $5.53. The company has a current ratio of 0.68, a quick ratio of 0.57 and a debt-to-equity ratio of 0.37. The company has a 50-day moving average of $0.49 and a 200-day moving average of $0.78. The firm has a market cap of $62.21 million, a price-to-earnings ratio of -0.14 and a beta of 0.76.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The business had revenue of $18.57 million during the quarter. Equities analysts forecast that bluebird bio will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of bluebird bio

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its position in bluebird bio by 38.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 325,111 shares of the biotechnology company’s stock valued at $416,000 after acquiring an additional 90,139 shares in the last quarter. SG Americas Securities LLC grew its position in bluebird bio by 458.8% in the first quarter. SG Americas Securities LLC now owns 80,032 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 65,710 shares in the last quarter. Vanguard Group Inc. grew its position in bluebird bio by 19.6% in the first quarter. Vanguard Group Inc. now owns 10,498,460 shares of the biotechnology company’s stock valued at $13,438,000 after acquiring an additional 1,723,081 shares in the last quarter. American International Group Inc. grew its position in bluebird bio by 77.4% in the first quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 41,177 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in shares of bluebird bio by 113.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock worth $71,000 after buying an additional 29,113 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.